Psychedelic Sector Insights

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond.

PSYCHEDELIC ALPHA

An Introduction to the Psychedelic Renaissance

40% of American adults report struggling with mental health or substance abuse disorders. Psychedelics may provide solutions to the global mental health and wellbeing crisis.

After decades of repression, psychedelic research is thriving.

Promising research has already resulted in FDA Breakthrough Therapy designations for psilocybin-assisted therapies aimed at treating depression, and MDMA-assisted psychotherapy for PTSD. Research on other ‘psychedelics’, including MDMA and LSD, is picking up pace with research centres at prestigious institutions—including Johns Hopkins and Imperial College London—driving a new wave of psychedelic research.

Decriminalisation and legalisation campaigns are succeeding.

In 2020 U.S. state of Oregon voted to decriminalise psychedelics and legalise Psilocybin Therapy. Washington, D.C., home of the White House, also decriminalised psychedelics, with many other states and localities poised to follow suit. Canada’s Health Minister has granted exemptions to allow access to psilocybin-assisted psychotherapy, setting precedent for future efforts to expand access.

Significant clinical trial milestones on the horizon.

In a Phase 3 MDMA-assisted therapy for PTSD trial that published last year, 88% of participants responded to the treatment. The trial’s sponsor, MAPS, expects to seek FDA approval as early as 2023. Multiple trials of psilocybin for depression are in Phase 2 or entering Phase 3, and are indicating preliminary safety and efficacy.

Psychedelics have the potential to address depression anxiety addiction PTSD chronic pain

Welcome to the Psychedelic Renaissance.

The Psychedelic Renaissance in Context

Today’s psychedelic renaissance benefits from a rich legacy of psychedelic research and usage dating back to pre-historic times.

The extensive psychedelic research and experimentation of the 1950s and ’60s represents a significant endowment, with today’s researchers taking up the torch.

1943

Albert Hofmann intentionally ingests LSD, experiencing the effects while cycling home. “Bicycle Day” is coined.

mid 1960s – 1971

Psychedelics criminalised, with Nixon declaring a War on Drugs in 1971 and a UN Convention following suit.

~10,000 BCE

Psychedelic iconography, such as mushrooms, appear in etched murals dating 10,000 BCE.

1950s and ’60s

Fertile decades for psychedelics research and experimentation, particularly in the U.S.

21st Century

Psychedelic renaissance emerges, with a return to human studies of psychedelics and decriminalisation campaigns.

Our Latest Analysis

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees?

This week: COMPASS Pathways survives challenges to two of its patents covering Polymorph A; MindMed is granted a patent covering candyflipping; we look at whether psychedelics companies will protect access to abortions; and more…

Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to Change Your Mind Comes to Netflix

This week: We’re launching an Opinions Column; How to Change Your Mind is coming to Netflix; and more…

Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design

This week: a new study from Yale finds efficacy in DMT for depression while skimping on set and setting; Cybin acquires Entheon’s Phase 1 DMT study; FDA snubs Mydecine’s Seamess Trial Design; and more…

Receive Our Updates

Join our Newsletter

Psychedelic insights, commentary and analysis delivered to your inbox, including our weekly Bulletin.

Follow Us on Twitter

Join us on Twitter where we share the latest news and analysis, covering the entire psychedelic space.

Axios Logo
Business Insider logo grey
New York Times
Mother Jones Logo
Rolling Stone Logo
Finimize logo grey
Vice Logo